Caffeine–Nicotine as a Neurochemical Bridge: Conceptual Framework with an Illustrative Self-Observation (Non-Clinical, Hypothesis-Generating)

Early antipsychotic and SSRI treatment can induce cognitive, sexual, and affective dysfunction, threatening adherence.We propose a mechanistic hypothesis in which nicotine (via 42/7 nAChR agonism) and caffeine (via adenosine A1/A2A receptor antagonism) transiently reverse antipsychotic-induced dopaminergic and cholinergic suppression by directly stimulating prefrontal/striatal dopamine release and glutamatergic transmission, thereby bypassing pharmacologically inhibited pathways.This compensatory modulation may serve as a functional "bridge" during early treatment, improving tolerability and adherence, rapidly improving key treatment-emergent adverse effects such as reduced libido, cognitive slowing, affective flattening, and urinary hesitancy, potentially improving early tolerability and adherence.A clinical case is presented for illustrative purposes, showing rapid subjective improvement in symptoms after self-administered nicotine and caffeine.This hypothesis is mechanistically grounded in established neuropharmacology, suggests a novel synergistic approach and warrants further validation in controlled studies.In contrast to traditional dopaminergic agents (e.g., cabergoline, modafinil, bupropion), which are frequently associated with adverse effects such as psychosis, behavioral dysregulation, and dependence liability (Table 2), the nicotinecaffeine combination may represent a more tolerable and self-regulating neuromodulatory strategy suitable for exploratory therapeutic contexts.